KIORA PHARMACEUTICALS, INC. Severance Costs
KIORA PHARMACEUTICALS, INC. (KPRX) reported Severance Costs of $0 for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SeveranceCosts1 · last filed 2023-11-09
- KIORA PHARMACEUTICALS, INC. severance costs for the quarter ending 2023-09-30 was $0.00.
- KIORA PHARMACEUTICALS, INC. severance costs for the quarter ending 2023-06-30 was $0.00.
- KIORA PHARMACEUTICALS, INC. severance costs for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. severance costs for the quarter ending 2022-09-30 was $0.00.
| Period end | Severance Costs 3 month | Severance Costs 6 month | Severance Costs 9 month |
|---|---|---|---|
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $962.83K 10-Q · filed 2023-11-09 |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-08 | $962.83K 10-Q · filed 2023-08-08 | |
| 2022-03-31 | $962.83K 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |